Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation
Journal of Cardiovascular Electrophysiology · 2023
DOI: 10.1111/jce.15801 ↗At a glance
Multizentrische Studie in Journal of Cardiovascular Electrophysiology, 2023. Written by Tarek Zghaib and 11 co-authors. Institution: Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Atrial Fibrillation, Thromboembolism, Catheter Ablation. Cited 1 times so far (Crossref); 11 references.
Abstract (original language)
Introduction
Pericardial bleeding is a rare but life‐threatening complication of atrial fibrillation (AF) ablation. Patients taking uninterrupted oral anticoagulation (AC) may be at increased risk for refractory bleeding despite pericardiocentesis and administration of protamine. In such cases, andexanet alfa can be given to reverse rivaroxaban or apixaban. In this study, we aim to describe the rate of acute hemostasis and thromboembolic complications with andexanet for refractory pericardial bleeding during AF ablation. Methods and Results In this multicenter, case series, participating centers identified patients who received a dose of apixaban or rivaroxaban within 24 h of AF ablation, developed refractory pericardial bleeding during the procedure despite pericardiocentesis and administration of protamine and received andexanet. Eleven patients met inclusion criteria, with mean age of 73.5 ± 5.3 years and median CHA 2 DS 2 ‐VASc score 4 [3–5]. All patients received protamine and pericardiocentesis, and 9 (82%) received blood products. All patients received a bolus of andexanet followed, in all but one, by a 2‐h infusion. Acute hemostasis was achieved in eight patients (73%) while three required emergent surgery. One patient (9%) experienced acute ST‐elevation myocardial infarction after receiving andexanet. Therapeutic AC was restarted after a mean of 2.2 ± 1.9 days and oral AC was restarted after a mean of 2.9 ± 1.6 days, with no recurrent bleeding.
Conclusion
In patients on uninterrupted apixaban or rivaroxaban, who develop refractory pericardial bleeding during AF ablation, andexanet can achieve hemostasis thereby avoiding the need for emergent surgery. However, there is a risk of thromboembolism following administration.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Cardiac Arrhythmia Unit, Heart Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Division of Cardiovascular Medicine, Section of Electrophysiology, School of Medicine, University of Colorado, Aurora, Colorado, USA.
ORCID profiles: Christopher Barrett, Jeffrey Arkles, Wendy Tzou, David S Frankel
Cite
APA
Zghaib, T., Allison, J. D., Barrett, C., Arkles, J., D'Souza, B., Luebbert, J., Garcia, F., Heist, E. K., Tzou, W., Callans, D., Marchlinski, F. E., & Frankel, D. S. (2023). Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.15801
Vancouver
Zghaib T, Allison JD, Barrett C, Arkles J, D'Souza B, Luebbert J, et al. Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology. 2023. doi:10.1111/jce.15801
BibTeX
@article{Zghaib2023,
author = {Zghaib, Tarek and Allison, John D and Barrett, Christopher and Arkles, Jeffrey and D'Souza, Benjamin and Luebbert, Jeffrey and Garcia, Fermin and Heist, E Kevin and Tzou, Wendy and Callans, David and Marchlinski, Francis E and Frankel, David S},
title = {Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation},
journal = {Journal of Cardiovascular Electrophysiology},
year = {2023},
doi = {10.1111/jce.15801}
}
EUVIMED